MGTX Stock Analysis: MeiraGTx Holdings | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 844m USD | 12M Return: 10.9% | KYG596651029 | Charts, Fundamentals & Technical Analysis

Gene Therapy, Ocular Treatments, Neurodegenerative Treatments, Cell Therapies
Total Rating 41
Safety 29
Buy Signal -1.13
Biotechnology
Sub-Industry Rotation: +3.3
Market Cap: 844M
Avg Turnover: 5.90M
Risk 3d forecast
Volatility66.1%
VaR 5th Pctl11.2%
VaR vs Median3.06%
Reward TTM
Sharpe Ratio0.34
Rel. Str. IBD20.2
Rel. Str. Peer Group35.3 pctl
Character TTM
Beta1.473
Beta Downside1.443
Hurst Exponent0.532
Choppyness37.9%
Drawdowns 3y
Max DD47.07%
CAGR/Max DD0.33
CAGR/Mean DD0.82
EPS (Earnings per Share) EPS (Earnings per Share) of MGTX over the last years for every Quarter: "2021-09": -0.59, "2021-12": -0.22, "2022-03": -0.7, "2022-06": -0.76, "2022-09": -0.83, "2022-12": -0.6, "2023-03": -0.62, "2023-06": -0.53, "2023-09": -0.74, "2023-12": -0.42, "2024-03": -0.77, "2024-06": -0.76, "2024-09": -0.55, "2024-12": -0.5, "2025-03": -0.51, "2025-06": -0.48, "2025-09": -0.62, "2025-12": 0.19, "2026-03": -0.57, "2026-06": 1.71, "2026-09": -0.53,
Last SUE: -0.09
Qual. Beats: 0
Revenue Revenue of MGTX over the last years for every Quarter: 2021-09: 6.947, 2021-12: 21.043, 2022-03: 5.633, 2022-06: 10.759, 2022-09: 4.816, 2022-12: -5.288, 2023-03: 3.334, 2023-06: 3.54, 2023-09: 5.103, 2023-12: 2.04, 2024-03: 0.697, 2024-06: 0.282, 2024-09: 10.91, 2024-12: 21.39, 2025-03: 1.926, 2025-06: 3.691, 2025-09: 0.41, 2025-12: 75.364, 2026-03: 0.293, 2026-06: 321.434, 2026-09: null,
Rev. CAGR: 221.39%
Rev. Trend: 90.8%
Last SUE: 4.00
Qual. Beats: 1

Warnings

Earnings Expected To Drop (P/E To P/E Forward)
Strong Share Dilution
Beneish M-Score Likely Earnings Manipulation
Fakeout
Below Avwap Earnings
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 8.4 years of data, until 10/2026

Jan -3.5% 18
Feb +1.8% 0
Mar -2.1% 5
Apr +0.8% 5
May +1.2% 0
Jun +5.1% 0
Jul -2.0% 0
Aug -1.9% 0
Sep +1.0% 0
Oct -6.0% 10
Nov -1.1% 0
Dec +4.7% 5

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: MGTX MeiraGTx Holdings

MeiraGTx Holdings plc is a clinical-stage biotechnology company developing gene therapies for serious diseases. Founded in 2015 and headquartered in New York, the company uses adeno-associated virus (AAV) vectors to deliver genetic treatments, a common approach in the gene therapy field where clinical-stage firms typically rely on partnerships and capital markets for funding before commercial revenue begins.

The companys pipeline spans multiple therapeutic areas, with a primary focus on ocular diseases. Clinical-stage programs include AAV-GAD for Parkinsons disease, AAV-RPE65 for retinal dystrophy, and AAV-CNGB3 and AAV-CNGA3 for achromatopsia. Additional clinical work targets radiation-induced xerostomia and Sjogrens syndrome, while preclinical programs address conditions such as Bardet-Biedl syndrome, Leber congenital amaurosis, amyotrophic lateral sclerosis, Alzheimers disease, and age-related macular degeneration.

Beyond ocular and neurological programs, MeiraGTx operates a riboswitch platform for metabolic peptide delivery and develops cell therapies for oncology, autoimmune disease, and intractable pain. The company has commercial collaborations with Johnson & Johnson Innovative Medicine for inherited retinal disease gene therapies and with Hologen Limited for central nervous system gene therapies, including treatments for Parkinsons disease and genetic obesity disorders.

Headlines to Watch Out For
  • Phase 2 gene therapy readouts for Parkinsons and retinal diseases
  • Johnson & Johnson collaboration milestones boost partnership revenue
  • Rising cash burn raises dilution risk from equity offerings
Piotroski VR-10 (Strict) 4.5
Net Income: 79.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 68.42 > 1.0
NWC/Revenue: 40.31% < 20% (prev -16.75%; Δ 57.07% < -1%)
CFO/TA 0.03 > 3% & CFO 13.7m > Net Income 79.0m
Net Debt (-18.5m) to EBITDA (262.4m): -0.07 < 3
Current Ratio: 3.76 > 1.5 & < 3
Outstanding Shares: last quarter (93.8m) vs 12m ago 16.40% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 133.6% > 50% (prev 19.08%; Δ 114.5% > 0%)
Interest Coverage Ratio: 20.06 > 6 (EBIT TTM 250.2m / Interest Expense TTM 12.5m)
Altman Z'' 3.78
A: 0.40 (Total Current Assets 218.3m - Total Current Liabilities 58.1m) / Total Assets 396.4m
B: -1.77 (Retained Earnings -701.8m / Total Assets 396.4m)
C: 0.84 (EBIT TTM 250.2m / Avg Total Assets 297.6m)
D: 1.19 (Book Value of Equity 215.6m / Total Liabilities 180.7m)
Altman-Z'' = 3.78 = AA
Beneish M 1.00
DSRI: 0.62 (Receivables 44.3m/6.79m, Revenue 397.5m/37.9m)
GMI: 0.27 (GM 26.56% / 97.19%)
AQI: 2.03 (AQ_t 0.11 / AQ_t-1 0.05)
SGI: 10.48 (Revenue 397.5m / 37.9m)
TATA: 0.16 (NI 79.0m - CFO 13.7m) / TA 396.4m)
Beneish M = 3.43 (Cap -4..+1) = D
What is the price of MGTX shares?

As of November 17, 2026, the stock is trading at USD 8.74 with a total of 706,057 shares traded. Over the past week, the price has changed by -7.90%, over one month by -5.82%, over three months by -36.53% and over the past year by +10.91%.

Current recommended Stop Loss: 8.00 (which is 8.5% or 1.3 ATR below the current price).

Is MGTX a buy, sell or hold?

MeiraGTx Holdings has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy MGTX.

  • StrongBuy: 5
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MGTX price?
Analysts Target Price 27.8 217.5%
MeiraGTx Holdings (MGTX) - Fundamental Data Overview as of 14 November 2026
Market Cap USD = 844.2m (844.2m USD * 1.0 USD.USD)
P/E Trailing = 10.1034
P/E Forward = 64.1026
P/S = 2.1238
P/B = 4.3105
Revenue TTM = 397.5m USD
EBIT TTM = 250.2m USD
EBITDA TTM = 262.4m USD
Long Term Debt = 100.0m USD (from longTermDebt, last quarter)
Short Term Debt = 2.30m USD (from shortTermDebt, last quarter)
Debt = 124.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.3m
Net Debt = -18.5m USD (calculated: Debt 124.6m - CCE 143.2m)
Enterprise Value = 825.7m USD (844.2m + Debt 124.6m - CCE 143.2m)
Interest Coverage Ratio = 20.06 (Ebit TTM 250.2m / Interest Expense TTM 12.5m)
EV/FCF = 208.0x (Enterprise Value 825.7m / FCF TTM 3.97m)
FCF Yield = 0.48% (FCF TTM 3.97m / Enterprise Value 825.7m)
FCF Margin = 1.00% (FCF TTM 3.97m / Revenue TTM 397.5m)
Net Margin = 19.87% (Net Income TTM 79.0m / Revenue TTM 397.5m)
 Gross Margin = unknown ((Revenue TTM 397.5m - Cost of Revenue TTM 11.2m) / Revenue TTM)
 Tobins Q-Ratio = 2.08 (Enterprise Value 825.7m / Total Assets 396.4m)
Interest Expense / Debt = 10.01% (Interest Expense 12.5m / Debt 124.6m)
Taxrate = 1.45% (2.36m / 163.0m)
NOPAT = 246.6m (EBIT 250.2m * (1 - 1.45%))
Current Ratio = 3.76 (Total Current Assets 218.3m / Total Current Liabilities 58.1m)
Debt / Equity = 0.58 (Debt 124.6m / totalStockholderEquity, last quarter 215.6m)
Debt / EBITDA = -0.07 (Net Debt -18.5m / EBITDA 262.4m)
Debt / FCF = -4.67 (Net Debt -18.5m / FCF TTM 3.97m)
Total Stockholder Equity = 27.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.54% (Net Income 79.0m / Total Assets 396.4m)
RoE = 284.4% (Net Income TTM 79.0m / Total Stockholder Equity 27.8m)
RoCE = 195.9% (EBIT 250.2m / Capital Employed (Equity 27.8m + L.T.Debt 100.0m))
RoIC = 76.88% (NOPAT 246.6m / Invested Capital 320.8m)
WACC = 10.50% (E(844.2m)/V(968.9m) * Re(10.59%) + D(124.6m)/V(968.9m) * Rd(10.01%) * (1-Tc(0.01)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 93.77 | Cagr: 18.47%
[DCF] Terminal Value 68.30% ; FCFF base≈3.97m ; Y1≈3.99m ; Y5≈4.22m
[DCF] Fair Price = 0.69 (EV 48.1m - Net Debt -18.5m = Equity 66.6m / Shares 96.0m; r=10.50% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.09 | # QB: 0
Revenue Correlation: 90.79 | Revenue CAGR: 221.4% | SUE: 4.0 | # QB: 1
EPS current Year (2026-12-31): EPS=0.51 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+135.9% | GrowthRev=+314.2%
EPS next Year (2027-12-31): EPS=-1.52 | Chg30d=-9.71% | Revisions=+25% | GrowthEPS=-399.0% | GrowthRev=-80.2%
[Analyst] Revisions Ratio: +50% (up=3, down=0)